Literature DB >> 20724115

Hypomethylation and overexpression of CD70 (TNFSF7) in CD4+ T cells of patients with primary Sjögren's syndrome.

Heng Yin1, Ming Zhao, Xiaoyan Wu, Fei Gao, Yongqi Luo, Le Ma, Sufang Liu, Guangsen Zhang, Jinwei Chen, Fen Li, Xiaoxia Zuo, Qianjin Lu.   

Abstract

BACKGROUND: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration and the production of autoantibodies, leading to the destruction of lacrimal and salivary glands. However, very little is known about the pathogenesis of the disorder. CD70 (TNFSF7), a B cell costimulatory molecule, is overexpressed in CD4(+) T cells from patients with systemic erythematosus lupus (SLE) due to the hypomethylation of its promoter.
OBJECTIVE: In this study we asked whether the epigenetic regulation of CD70 expression is abnormal in pSS.
METHODS: CD70 levels in CD4(+) T cells from pSS patients, tinea pedis and healthy controls were measured by real-time RT-PCR and flow cytometry. Bisulphite sequencing was performed to determine the methylation status of the TNFSF7 promoter region.
RESULTS: CD70 expression was significantly elevated and correlated with a decrease in TNFSF7 promoter methylation in pSS CD4(+) T cells compared to controls.
CONCLUSIONS: Demethylation of the CD70 promoter regulatory elements contributes to CD70 overexpression in pSS CD4(+) T cells, and may contribute to autoreactivity. Copyright 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724115     DOI: 10.1016/j.jdermsci.2010.06.011

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  23 in total

Review 1.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

Review 2.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

3.  Correlation between miR-126 expression and DNA hypomethylation of CD4+ T cells in rheumatoid arthritis patients.

Authors:  Ge Yang; Daoquan Wu; Guang Zeng; Ou Jiang; Pingzong Yuan; Shenjie Huang; Jing Zhu; Jie Tian; Yaguang Weng; Zhihua Rao
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents.

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Int J Clin Rheumtol       Date:  2011-08

Review 5.  Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve?

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Expert Rev Clin Immunol       Date:  2015-01       Impact factor: 4.473

Review 6.  Genome-wide approaches (GWA) in oral and craniofacial diseases research.

Authors:  H Kim; S Gordon; R Dionne
Journal:  Oral Dis       Date:  2012-08-23       Impact factor: 3.511

7.  Genetics and epigenetics in primary Sjögren's syndrome.

Authors:  Juliana Imgenberg-Kreuz; Astrid Rasmussen; Kathy Sivils; Gunnel Nordmark
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

8.  The role of epigenetic mechanisms and processes in autoimmune disorders.

Authors:  Judith M Greer; Pamela A McCombe
Journal:  Biologics       Date:  2012-09-06

Review 9.  Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions.

Authors:  Chary López-Pedrera; Carlos Pérez-Sánchez; Manuel Ramos-Casals; Monica Santos-Gonzalez; Antonio Rodriguez-Ariza; Ma José Cuadrado
Journal:  Clin Dev Immunol       Date:  2011-09-14

Review 10.  The contribution of epigenetics in Sjögren's Syndrome.

Authors:  Orsia D Konsta; Yosra Thabet; Christelle Le Dantec; Wesley H Brooks; Athanasios G Tzioufas; Jacques-Olivier Pers; Yves Renaudineau
Journal:  Front Genet       Date:  2014-04-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.